Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-Alfatide vs 18F-FDG PET/CT for NSCLC Lymph Node Metastasis
NCT06416852Phase 3Not yet recruiting
- Sponsor
- Yantai Lannacheng Biotechnology Co., Ltd.
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of 18f-alfatide in non-small cell lung cancer (NSCLC), sponsored by Yantai Lannacheng Biotechnology Co., Ltd.. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
18f-alfatide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06416852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06416852.